The B case describes the events – including the offers and the negotiation – leading up to Sundown’s acquisition of Cyna for US$40.50 per share in cash or US$624 million (approximately C$841 million) – a 120% premium over the closing price of just over US$18 a share before the deal was announced. The case also brings the reader up to date on the turns Anthony’s life has taken since the acquisition and some of the exciting ventures in which he is now involved.
Keywords
Entrepreneurship, Leadership, Biopharmaceutical, Initial Public Offering, Clinical Trial, Funding, Acquisition, Finance
Settings
Canada
Cyna Pharma (Disguised), Healthcare, Biopharmaceuticals
2002–2016
Available Languages
English
Copyright Information
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
